Cagrilintide + Tirzepatide Stack Protocol - Amylin + Dual Incretin

Cagrilintide + Tirzepatide Stack Quick Reference

What Is the Cagrilintide + Tirzepatide Stack?

The cagrilintide + tirzepatide stack is a community-derived 3-receptor weight-management protocol combining cagrilintide (a long-acting amylin/calcitonin receptor agonist) with tirzepatide (a dual GLP-1/GIP receptor agonist). This combination activates three receptor families: amylin/calcitonin signaling plus GLP-1 and GIP incretin signaling.

This stack sits between CagriSema (2-receptor with Phase 3 human data) and cagrilintide + retatrutide (4-receptor, fully speculative). The main hypothesis is that adding amylin satiety signaling to tirzepatide's stronger dual-incretin platform can outperform either monotherapy approach in selected users.

No human clinical trial has tested cagrilintide + tirzepatide directly. Protocol design is extrapolated from individual compound data, CagriSema combination logic, and preclinical combination evidence reported at ADA 2024.

Why Add Cagrilintide to Tirzepatide?

Dual Incretin Foundation - What Tirzepatide Already Provides

Tirzepatide is the strongest FDA-approved monotherapy option for obesity and has outperformed semaglutide in comparative programs. It combines GLP-1 receptor activation (appetite suppression and gastric-emptying delay) with GIP receptor activation (metabolic-efficiency and insulin-sensitivity support). See the full tirzepatide protocol page for monotherapy data.

The Missing Pathway - Brainstem Amylin Satiety

Tirzepatide does not activate amylin receptors. Cagrilintide adds amylin/calcitonin pathway signaling in hindbrain satiety circuits that are mechanistically distinct from incretin-only signaling.

Preclinical Synergy Data - ADA 2024

Valdecantos et al. (ADA 2024) reported that submaximal-dose cagrilintide + tirzepatide produced greater weight reduction in obese rats than either compound alone, with additional improvement in selected metabolic markers. This is supportive but preclinical-only evidence.

Triple Gastric Emptying Convergence

Cagrilintide and tirzepatide both slow gastric emptying through different receptor pathways. This can increase satiety but also creates the primary tolerability bottleneck for this stack.

Cagrilintide + Tirzepatide Dosing Protocol & Schedule

Format A: Separate Vials - Staggered Co-Titration

Staggered titration is recommended: establish tirzepatide tolerance first, then introduce cagrilintide and escalate both gradually.

Protocol Notes

• Injection logistics: Both compounds are subcutaneous and typically once weekly; use different sites.
• Oral options: Neither compound is orally bioavailable in injectable form.
• Sub-maximal dosing rationale: preclinical data suggests combination benefit can appear before maximal monotherapy doses.
• Do not combine with semaglutide: tirzepatide already includes GLP-1 receptor agonism.
• Do not combine with pramlintide: cagrilintide already covers amylin agonism.

Cagrilintide + Tirzepatide Reconstitution Guide

Format A: Separate Vials

Math verification (Tirzepatide 10 mg vial, 1.0 mL BAC): concentration = 10,000 mcg/mL. 5.0 mg dose = 0.50 mL (50 units). 15.0 mg dose = 1.50 mL (150 units).

Math verification (Cagrilintide 5 mg vial, 2.0 mL BAC): concentration = 2,500 mcg/mL. 2.4 mg dose = 0.96 mL (96 units).

7-Step Reconstitution Instructions

1. Allow vials to reach room temperature for about 10-15 minutes.
2. Disinfect stoppers with alcohol and allow to dry.
3. Draw BAC water per target concentration table.
4. Inject BAC slowly down vial wall, especially for cagrilintide.
5. Gently swirl or roll; do not shake either compound.
6. Inspect for clear, colorless solution and discard if cloudy or particulate.
7. Label each vial with compound, concentration, and date; refrigerate at 2-8 C and use within 28-30 days.

Cagrilintide + Tirzepatide Side Effects & Safety

No human trial has evaluated this exact combination. Side-effect expectations are extrapolated from single-agent data and CagriSema-level combination context.

• Compounded GI burden: high rates of nausea, vomiting, diarrhea, and constipation are expected during co-escalation.
• Gastroparesis concern: dual-pathway gastric slowing is the most important theoretical risk.
• Injection-site reactions: more commonly associated with cagrilintide; rotation remains important.
• Gallbladder events: aggressive weight loss may increase cholelithiasis risk.
• Pancreatitis (class concern): tirzepatide carries GLP-1 class warnings and monitoring expectations.
• Multi-source quality risk: cagrilintide remains investigational; non-pharma tirzepatide quality is variable.

Clinical Evidence Context

This stack is a 3-receptor pathway model: amylin-driven satiety plus GLP-1/GIP incretin signaling. Combination evidence in humans is still absent.

Storage & Handling

Limiting factor: cagrilintide handling sensitivity (do not shake) is the stricter practical constraint even though refrigerated windows are similar.

Cagrilintide + Tirzepatide vs. CagriSema vs. Cagrilintide + Retatrutide

Decision Guidance

• Choose Cagrilintide + Tirzepatide when prioritizing a pragmatic speculative model built around an FDA-approved incretin base plus amylin layering.
• Choose CagriSema when prioritizing highest combination evidence strength and lower uncertainty.
• Choose Cagrilintide + Retatrutide only for maximum receptor-coverage experimentation with higher complexity and uncertainty.

Related Stacking Protocols

CagriSema (Cagrilintide + Semaglutide)

The evidence-backed parent combination with Phase 3 data and regulatory review momentum. View CagriSema stack.

Cagrilintide + Retatrutide Stack

Higher-complexity, broader-coverage variant that adds glucagon receptor agonism. View Cagrilintide + Retatrutide stack.

Higher-Dose CagriSema (2.4/7.2 mg)

A pharmaceutical escalation path under investigation to narrow efficacy gaps with stronger incretin programs.

Frequently Asked Questions - Cagrilintide + Tirzepatide Stack

Sources & Research

1. Valdecantos P, Rada P, Ghosh S, Rondinone CM, Valverde AM. "300-OR: Beneficial Effect of the Combination Therapy of Cagrilintide, a Dual Amylin/Calcitonin Agonist, and Tirzepatide, a Dual GLP-1/GIP Agonist, on Body Weight Loss in Obese Rats." Diabetes, 2024 Link.
2. Garvey WT, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2025 Link.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022 Link.
4. Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management." The Lancet, 2021 Link.
5. Enebo LB, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg." The Lancet, 2021 Link.
6. Kruse T, Dahl K, Schaffer L, et al. "Development of Cagrilintide, a Long-Acting Amylin Analogue." Journal of Medicinal Chemistry, 2021 Link.
7. Garvey WT, Frias JP, Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)." The Lancet, 2023 Link.
8. Novo Nordisk "CagriSema demonstrated 23% weight loss in REDEFINE 4 vs. tirzepatide 25.5%." Press Release, 2026.
9. Dutta D, et al. "Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide as Anti-Obesity Medications: A Systematic Review and Meta-Analysis." Indian Journal of Endocrinology and Metabolism, 2024.
10. ClinicalTrials.gov — (NCT05567796), (NCT06131437), (NCT04184622).

Related Protocols

Disclaimer